{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:45:12Z","timestamp":1761101112950},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0065981","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T21:13:03Z","timestamp":1371589983000},"page":"e65981","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation"],"prefix":"10.1371","volume":"8","author":[{"given":"Hua","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e40853","DOI":"10.1371\/journal.pone.0040853","article-title":"Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells","volume":"7","author":"DB Lipka","year":"2012","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/107327480901600207","article-title":"Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities","volume":"16","author":"HF Fernandez","year":"2009","journal-title":"Cancer Control"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/bmt.2008.105","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007","volume":"42","author":"J Goldman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"M Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref7","first-page":"S31","article-title":"Advanced CML: therapeutic options for patients in accelerated and blast phases","volume":"6","author":"NP Shah","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","article-title":"Current and emerging treatment options in chronic myeloid leukemia","volume":"109","author":"E Jabbour","year":"2007","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation","volume":"99","author":"DJ Weisdorf","year":"2002","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2008-07-163212","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation","volume":"113","author":"O Ringden","year":"2009","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"M Robin","year":"2005","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1701607","article-title":"Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation","volume":"23","author":"JL Steegmann","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V90.7.2549","article-title":"Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation","volume":"90","author":"CS Higano","year":"1997","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1705554","article-title":"Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis","volume":"39","author":"F Palandri","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"RH Collins Jr","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"C Guglielmi","year":"2002","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"F Dazzi","year":"2000","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bmt.1703883","article-title":"Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions","volume":"31","author":"AM Raiola","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"ref19","first-page":"1072","article-title":"Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation","volume":"85","author":"J Roman","year":"2000","journal-title":"Haematologica"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2302\/kjm.52.182","article-title":"Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation","volume":"52","author":"AJ Ullmann","year":"2003","journal-title":"Keio J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","article-title":"Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation","volume":"16","author":"MP Wright","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"G Hess","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.leukres.2009.03.010","article-title":"Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation","volume":"33","author":"A Sekhri","year":"2009","journal-title":"Leuk Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"E Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"DJ DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref26","first-page":"663","article-title":"A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"M Weisser","year":"2006","journal-title":"Haematologica"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"BN Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00277-010-1081-3","article-title":"Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China","volume":"90","author":"QF Liu","year":"2011","journal-title":"Ann Hematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-5-46","article-title":"Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies","volume":"5","author":"L Xuan","year":"2012","journal-title":"J Hematol Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia","volume":"4","author":"NL Komarova","year":"2009","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"X An","year":"2010","journal-title":"Leuk Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bbmt.2009.06.017","article-title":"Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia","volume":"15","author":"QF Liu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"HJ Kolb","year":"1990","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","article-title":"Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia","volume":"330","author":"DL Porter","year":"1994","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.beha.2006.10.002","article-title":"Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment","volume":"20","author":"F Dazzi","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"HM Kantarjian","year":"2002","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/00007890-199311000-00013","article-title":"Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation","volume":"56","author":"B Hertenstein","year":"1993","journal-title":"Transplantation"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705063","article-title":"Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Espanol de Trasplante Hemopoyetico)","volume":"36","author":"C Martinez","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1100\/2011\/924954","article-title":"Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside","volume":"11","author":"J Olivieri","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.leukres.2012.09.006","article-title":"Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of \u201ccure\u201d","volume":"36","author":"M Breccia","year":"2012","journal-title":"Leuk Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"N Takahashi","year":"2011","journal-title":"Haematologica"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response","volume":"36","author":"H-Y Yhim","year":"2012","journal-title":"Leuk Res"},{"key":"ref43","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"S Merante","year":"2005","journal-title":"Haematologica"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"P Rousselot","year":"2007","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"E Olavarria","year":"2007","journal-title":"Blood"},{"key":"ref47","first-page":"215","article-title":"[Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation]","volume":"53","author":"T Igarashi","year":"2012","journal-title":"Rinsho Ketsueki"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy","volume":"50","author":"HG Goh","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.leukres.2011.01.001","article-title":"Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia","volume":"35","author":"Y Luo","year":"2011","journal-title":"Leuk Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2004-01-0027","article-title":"Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance","volume":"105","author":"H Wang","year":"2005","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2009.016766","article-title":"Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia","volume":"95","author":"W Deenik","year":"2010","journal-title":"Haematologica"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"DL Forrest","year":"2009","journal-title":"Leuk Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0065981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T18:20:46Z","timestamp":1595960446000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0065981"}},"subtitle":[],"editor":[{"given":"Connie J.","family":"Eaves","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0065981","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}